Cancer chemotherapy: A critical analysis of its 60 years of history

Critical Reviews in Oncology/Hematology

Volumn 84, Issue 2, 2012, Pages 181-199

  Galmarini, Darío ^a   Galmarini, Carlos M ^a,b   Galmarini, Felipe C ^a  

^a Fundación Marcel Dargent Escuela Sudamericana de Oncología Montevideo   (Argentina)

^b PHARMAMAR S A   (Spain)

Author keywords

Cancer; Chemotherapy; History

Indexed keywords

ALKYLATING AGENT; ALPHA INTERFERON; AMINOPTERIN; ANTINEOPLASTIC ANTIMETABOLITE; BLEOMYCIN; CARBOPLATIN; CHLORMETHINE; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DACTINOMYCIN; DASATINIB; ERLOTINIB; FLOXURIDINE; FLUOROURACIL; FOLIC ACID ANTAGONIST; FOLINIC ACID; GEFITINIB; IMATINIB; MERCAPTOPURINE; METHOTREXATE; NILOTINIB; PLACEBO; PREDNISONE; PROCARBAZINE; SORAFENIB; THIOTEPA; UNINDEXED DRUG; VINBLASTINE; VINCRISTINE;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ANUS TUMOR; BREAST METASTASIS; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; CANCER RESISTANCE; CHORIOCARCINOMA; CHRONIC MYELOID LEUKEMIA; CONTINUOUS INFUSION; DISEASE FREE SURVIVAL; DRUG DESIGN; DRUG INTERMITTENT THERAPY; EVIDENCE BASED MEDICINE; FIBROSARCOMA; GASTROINTESTINAL STROMAL TUMOR; HODGKIN DISEASE; HUMAN; KIDNEY CARCINOMA; LEUKEMIA REMISSION; LIVER CELL CARCINOMA; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; MICROMETASTASIS; MOLECULARLY TARGETED THERAPY; NONHODGKIN LYMPHOMA; OSTEOSARCOMA; OVERALL SURVIVAL; PHARMACOGENOMICS; REVIEW; SEMINOMA; SQUAMOUS CELL CARCINOMA; TESTIS CANCER; TRANSLATIONAL RESEARCH; TROPHOBLASTIC TUMOR; TUMOR REGRESSION;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DRUG RESISTANCE, NEOPLASM; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASMS; TREATMENT OUTCOME;

EID: 84867843579     PISSN: 10408428     EISSN: 18790461     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2012.03.002     Document Type: Review

References (216)

1. Farber S., Diamond L.K. Temporary remissions in acute leukemia in children produced by folic acid antagonist, 4-aminopteroyl-glutamic acid. N Engl J Med 1948, 238:787-793.
2. Gilman A. Therapeutic applications of chemical warfare agents. Fed Proc 1946, 5:285-292.
3. Law L.W. Response of a resistant variant of leukemic cells to an antagonist of pteroylglutamic acid. Proc Soc Exp Biol Med 1951, 77:340-344.
4. Philips F.S. Recent contributions to the pharmacology of bis(2-haloethyl) amines and sulfides. J Pharmacol Exp Ther 1950, 99:281-323.
5. Seeger D.R., Smith J.M., Hultquist M.E. Antagonist for pteroylglutamic acid. J Am Chem Soc 1947, 69:2567.
6. Stevens C.M., Mylorie A., Auerbach C., et al. Biological action of 'mustard gas' compounds. Nature 1950, 166:1019-1021.
7. Farber S. Some observations on the effect of folic acid antagonists on acute leukemia and other forms of incurable cancer. Blood 1949, 4:160-167.
8. Elion G.B., Hitchings G.H., Vanderwerff H. Antagonists of nucleic acid derivatives. VI. Purines. J Biol Chem 1951, 192:505-518.
9. Burchenal J.H., Murphy M.L., Ellison R.R., et al. Clinical evaluation of a new antimetabolite, 6-mercaptopurine, in the treatment of leukemia and allied diseases. Blood 1953, 8:965-999.
10. Heidelberger C., Chaudhuri N.K., Danneberg P., et al. Fluorinated pyrimidines, a new class of tumour-inhibitory compounds. Nature 1957, 179:663-666.
11. Li M.C., Hertz R., Bergenstal D.M. Therapy of choriocarcinoma and related trophoblastic tumors with folic acid and purine antagonists. N Engl J Med 1958, 259:66-74.
12. Chabner B.A., Roberts T.G. Timeline: chemotherapy and the war on cancer. Nat Rev Cancer 2005, 5:65-72.
13. Morrison W.B. Cancer chemotherapy: an annotated history. J Vet Intern Med 2010, 24:1249-1262.
14. Gilman A., Philips F.S. The biological actions and therapeutic applications of the B-chloroethyl amines and sulfides. Science 1946, 103:409-415.
15. Goodman L.S., Wintrobe M.M., et al. Nitrogen mustard therapy; use of methyl-bis (beta-chloroethyl) amine hydrochloride and tris (beta-chloroethyl) amine hydrochloride for Hodgkin's disease, lymphosarcoma, leukemia and certain allied and miscellaneous disorders. J Am Med Assoc 1946, 132:126-132.
16. Gilman A. The initial clinical trial of nitrogen mustard. Am J Surg 1963, 105:574-578.
17. Gellhorn A., Hyman G.A., Ultmann J.E. Chlorambucil in treatment of chronic lymphocytic leukemia and certain lymphomas. J Am Med Assoc 1956, 162:178-183.
18. Pinkel D. Cyclophosphamide in children with cancer. Cancer Chemother Rep 1961, 12:187-190.
19. Watson J.D., Crick F.H. Molecular structure of nucleic acids; a structure for deoxyribose nucleic acid. Nature 1953, 171:737-738.
20. Lajtha L.G., Schofield R. Proliferative capacity of hematopoietic stem cells. Normal and malignant cell growth 1969, Springer-Verlag, New York. R.J. Fry, M.L. Griem, W.H. Kirsten (Eds.).
21. Lesher S.W., Bauman J. Cell proliferation in the intestinal epithelium 1969, Springer-Verlag, New York. R.J. Fry, M.L. Griem, W.H. Kirsten (Eds.).
22. Bernard J., Boiron M., Jacquillat C., Weil M., Najean Y. A new agent active in the treatment of acute leukemia: cytosine arabinoside. Presse Med 1966, 74:799-802.
23. Bonadonna G., Monfardini S., De Lena M., Fossati-Bellani F. Clinical evaluation of adriamycin, a new antitumour antibiotic. Br Med J 1969, 3:503-506.
24. Dimarco A., Gaetani M., Orezzi P., et al. 'Daunomycin', a new antibiotic of the rhodomycin group. Nature 1964, 201:706-707.
25. Falkson G., de Villiers P.C., Falkson H.C., Fichardt T. Natulan (Procarbazine) combined with radiotherapy in management of inoperable malignant melanoma. Br Med J 1965, 2:1473-1474.
26. Johnson I.S., Armstrong J.G., Gorman M., Burnett J.P. The vinca alkaloids: a new class of oncolytic agents. Cancer Res 1963, 23:1390-1427.
27. Mathe G., Schweisguth O., Brule G., et al. Trial therapy of Hodgkin's disease and other malignant reticulo-histiocytic diseases by vincaleukoblastin. Presse Med 1962, 70:1349-1352.
28. Umezawa H., Ishizuka M., Maeda K., Takeuchi T. Studies on bleomycin. Cancer 1967, 20:891-895.
29. Felix W., Senn H.J. Clinical study of the new podophyllotoxin derivative, 4'-demethylepipodophyllotoxin 9-(4,6-o-ethylidene- beta-d-glucopyranoside) (NSC-141540; VP-16-213), in solid tumors. Cancer Chemother Rep 1975, 59:737-742.
30. Lippman A.J., Helson C., Helson L., Krakoff I.H. Clinical trials of cis-diamminedichloroplatinum (NSC-119875). Cancer Chemother Rep 1973, 57:191-200.
31. Holland J.F. The chemical control of cancer. Public Health Rep 1954, 69:1151-1166.
32. Baserga R., Henegar G.C., Kisieleski W.E., Lisco H. Uptake of tritiated thymidine by human tumors in vivo. Lab Invest 1962, 11:360-364.
33. Johnson H.A., Haymaker W.E., Rubini J.R., et al. A radioautographic study of a human brain and glioblastoma multiforme after the in vivo uptake of tritiated thymidine. Cancer 1960, 13:636-642.
34. Johnson H.A., Rubini J.R., Cronkite E.P., Bond V.P. Labeling of human tumor cells in vivo by tritiated thymidine. Lab Invest 1960, 9:460-465.
35. Killmann S.A., Cronkite E.P., Fliedner T.M., Bond V.P. Cell proliferation in multiple myeloma studied with tritiated thymidine in vivo. Lab Invest 1962, 11:845-853.
36. Lala P.K., Maloney M.A., Patt H.M. Measurement of DNA-synthesis time in myeloid-erythroid precursors. Exp Cell Res 1965, 38:626-634.
37. Lipkin M., Bell B., Sherlock P. Cell proliferation kinetics in the gastrointestinal tract of man. I. Cell renewal in colon and rectum. J Clin Invest 1963, 42:767-776.
38. Clarkson B., Ota K., Ohkita T., O'Connor A. Kinetics of proliferation of cancer cells in neoplastic effusions in man. Cancer 1965, 18:1189-1213.
39. McKinna J.A. An experimental approach to adjuvant chemotherapy in carcinoma of the rectum and colon. Proc R Soc Med 1967, 60:212-214.
40. Rubini J.R., Cronkite E.P., Bond V.P., Fliedner T.M. The metabolism and fate of tritiated thymidine in man. J Clin Invest 1960, 39:909-918.
41. Hoffman J., Post J. In vivo studies of DNA synthesis in human normal and tumor cells. Cancer Res 1967, 27:898-902.
42. Skipper H.E. The effects of chemotherapy on the kinetics of leukemic cell behavior. Cancer Res 1965, 25:1544-1550.
43. Skipper H.E., Bell M., Thomson J.R. Partial reversal of the antileukemic activity of A-methopterin by cortisone. Cancer Res 1954, 14:86-87.
44. Skipper H.E., Schabel F.M., Wilcox W.S. Experimental evaluation of potential anticancer agents. XIII. On the criteria and kinetics associated with "curability" of experimental leukemia. Cancer Chemother Rep 1964, 35:1-111.
45. Wilcox W.S., Schabel F.M., Skipper H.E. Experimental evaluation of potential anticancer agents XV. On the relative rates of growth and host kill of "single" leukemia cells that survive in vivo cytoxan therapy. Cancer Res 1966, 26:1009-1014.
46. Skipper H.E., Heidelberger C., Welch A.D. Some biochemical problems of cancer chemotherapy. Nature 1957, 179:1159-1162.
47. Skipper H.E., Thomson J.R., Bell M. Attempts at dual blocking of biochemical events in cancer chemotherapy. Cancer Res 1954, 14:503-507.
48. Leibman K.C., Heidelberger C. The metabolism of P32-labeled ribonucleotides in tissue slices and cell suspensions. J Biol Chem 1955, 216:823-830.
49. Rutman R.J., Cantarow A., Paschkis K.E. Studies in 2-acetylaminofluorene carcinogenesis. III. The utilization of uracil-2-C14 by preneoplastic rat liver and rat hepatoma. Cancer Res 1954, 14:119-123.
50. Mathe G., Schwarzenberg L., Mery A.M., et al. Extensive histological and cytological survey of patients with acute leukaemia in "complete remission." Br Med J 1966, 1:640-642.
51. Report to the British Medical Research Council by their Tuberculosis Chemotherapy Trials Committee: Various combinations of isoniazid with streptomycin or with P.A.S. in the treatment of pulmonary tuberculosis. Br Med J 1955;1:465-6.
52. Li M.C., Whitmore W.F., Golbey R., Grabstald H. Effects of combined drug therapy on metastatic cancer of the testis. JAMA 1960, 174:1291-1299.
53. De Lena M., De Palo G.M., Bonadonna G., Beretta G., Bajetta E. Therapy of metastatic mammary carcinoma with cyclophosphamide, methotrexate, vincristine and fluorouracil. Tumori 1973, 59:11-24.
54. Einhorn L.H., Donohue J. Cis-diamminedichloroplatinum, vinblastine, and bleomycin combination chemotherapy in disseminated testicular cancer. Ann Intern Med 1977, 87:293-298.
55. Einhorn L.H., Donohue J.P. Combination chemotherapy in disseminated testicular cancer: the Indiana University experience. Semin Oncol 1979, 6:87-93.
56. Frei E., Karon M., Levin R.H., et al. The effectiveness of combinations of antileukemic agents in inducing and maintaining remission in children with acute leukemia. Blood 1965, 26:642-656.
57. Devita V.T., Serpick A.A., Carbone P.P. Combination chemotherapy in the treatment of advanced Hodgkin's disease. Ann Intern Med 1970, 73:881-895.
58. Bonadonna G., Zucali R., Monfardini S., De Lena M., Uslenghi C. Combination chemotherapy of Hodgkin's disease with adriamycin, bleomycin, vinblastine, and imidazole carboxamide versus MOPP. Cancer 1975, 36:252-259.
59. Frei E., Holland J.F., Schneiderman M.A., et al. A comparative study of two regimens of combination chemotherapy in acute leukemia. Blood 1958, 13:1126-1148.
60. Goldie J.H., Coldman A.J. A mathematic model for relating the drug sensitivity of tumors to their spontaneous mutation rate. Cancer Treat Rep 1979, 63:1727-1733.
61. Li M.C. Current status of cancer chemotherapy. J Natl Med Assoc 1960, 52:315-320.
62. Mathe G., Schwarzenberg L., Amiel J.L., et al. Operational research in anticancer chemotherapy. Chemotherapy and strategy of treatment of cancer. Bull Mem Soc Med Hop Paris 1968, 119:133-158.
63. Cole W.H. Recurrence in carcinoma of the colon and proximal rectum following resection for carcinoma. AMA Arch Surg 1952, 65:264-270.
64. Fisher E.R, Turnbull R.B. The cytologic demonstration and significance of tumor cells in the mesenteric venous blood in patients with colorectal carcinoma. Surg Gynecol Obstet 1955, 100:102-108.
65. Roberts S., Jonasson O., Long L., Mc G.E., Mc G.R., Cole W.H. Relationship of cancer cell in the circulating blood to operation. Cancer 1962, 15:232-240.
66. Rousselot L.M., Cole D.R., Slattery J., Grossi C.E., Gonzalez E.M. Intraluminal chemotherapy adjuvant (HN2 or 5-FU) to operation for cancer of the colon and rectum. Follow-up report of 83 cases. Ann Surg 1965, 162:407-415.
67. Dwight R.W., Humphrey E.W., Higgins G.A., Keehn R.J. FUDR as an adjuvant to surgery in cancer of the large bowel. J Surg Oncol 1973, 5:243-249.
68. Holden W.D., Dixon W.J., Kuzma J.W. The use of triethylenethiophosphoramide as an adjuvant to the surgical treatment of colorectal carcinoma. Ann Surg 1967, 165:481-503.
69. Lawrence W., Terz J.J., Horsley S., et al. Chemotherapy as an adjuvant to surgery for colorectal cancer. Ann Surg 1975, 181:616-623.
70. Goldie J.H. Scientific basis for adjuvant and primary (neoadjuvant) chemotherapy. Semin Oncol 1987, 14:1-7.
71. Heuser L., Spratt J.S., Polk H.C. Growth rates of primary breast cancers. Cancer 1979, 43:1888-1894.
72. Shackney S.E., McCormack G.W., Cuchural G.J. Growth rate patterns of solid tumors and their relation to responsiveness to therapy: an analytical review. Ann Intern Med 1978, 89:107-121.
73. Speer J.F., Petrosky V.E., Retsky M.W., Wardwell R.H. A stochastic numerical model of breast cancer growth that simulates clinical data. Cancer Res 1984, 44:4124-4130.
74. Fisher B., Ravdin R.G., Ausman R.K., Slack N.H., Moore G.E., Noer R.J. Surgical adjuvant chemotherapy in cancer of the breast: results of a decade of cooperative investigation. Ann Surg 1968, 168:337-356.
75. Fisher B., Carbone P., Economou S.G., et al. 1-Phenylalanine mustard (L-PAM) in the management of primary breast cancer. A report of early findings. N Engl J Med 1975, 292:117-122.
76. Bonadonna G., Brusamolino E., Valagussa P., et al. Combination chemotherapy as an adjuvant treatment in operable breast cancer. N Engl J Med 1976, 294:405-410.
77. Jaffe N., Frei E., Traggis D., Bishop Y. Adjuvant methotrexate and citrovorum-factor treatment of osteogenic sarcoma. N Engl J Med 1974, 291:994-997.
78. Norton L., Simon R., Brereton H.D., Bogden A.E. Predicting the course of Gompertzian growth. Nature 1976, 264:542-545.
79. Kidwell J.F., Howard A., Laird A.K. The inheritance of growth and form in the mouse. II. The Gompertz growth equation. Growth 1969, 33:339-352.
80. Kopper L., Steel G.G. The therapeutic response of three human tumor lines maintained in immune-suppressed mice. Cancer Res 1975, 35:2704-2713.
81. Laird A.K. Dynamics of growth in tumors and in normal organisms. Natl Cancer Inst Monogr 1969, 30:15-28.
82. Steel G.G., Adams K., Barrett J.C. Analysis of the cell population kinetics of transplanted tumours of widely-differing growth rate. Br J Cancer 1966, 20:784-800.
83. Lala P.K. Age-specific changes in the proliferation of Ehrlich ascites tumor cells grown as solid tumors. Cancer Res 1972, 32:628-636.
84. Watson J.V. The cell proliferation kinetics of the EMT6/M/AC mouse tumour at four volumes during unperturbed growth in vivo. Cell Tissue Kinet 1976, 9:147-156.
85. Norton L. Implications of kinetic heterogeneity in clinical oncology. Semin Oncol 1985, 12:231-249.
86. Norton L. Conceptual and practical implications of breast tissue geometry: toward a more effective, less toxic therapy. Oncologist 2005, 10:370-381.
87. Lyman G.H., Barron R.L., Natoli J.L., Miller R.M. Systematic review of efficacy of dose-dense versus non-dose-dense chemotherapy in breast cancer, non-Hodgkin lymphoma, and non-small cell lung cancer. Crit Rev Oncol Hematol 2011.
88. Groffen J., Stephenson J.R., Heisterkamp N., de Klein A., Bartram C.R., Grosveld G. Philadelphia chromosomal breakpoints are clustered within a limited region, bcr, on chromosome 22. Cell 1984, 36:93-99.
89. Heisterkamp N., Stephenson J.R., Groffen J., et al. Localization of the c-ab1 oncogene adjacent to a translocation break point in chronic myelocytic leukaemia. Nature 1983, 306:239-242.
90. Lugo T.G., Pendergast A.M., Muller A.J., Witte O.N. Tyrosine kinase activity and transformation potency of bcr-abl oncogene products. Science 1990, 247:1079-1082.
91. Nowell P.C. Discovery of the Philadelphia chromosome: a personal perspective. J Clin Invest 2007, 117:2033-2035.
92. Druker B.J. Perspectives on the development of a molecularly targeted agent. Cancer Cell 2002, 1:31-36.
93. Druker B.J., Guilhot F., O'Brien S.G., et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 2006, 355:2408-2417.
94. O'Brien S.G., Guilhot F., Larson R.A., et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003, 348:994-1004.
95. Blanke C.D., Demetri G.D., von Mehren M., et al. Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT. J Clin Oncol 2008, 26:620-625.
96. Blanke C.D., Rankin C., Demetri G.D., et al. Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033. J Clin Oncol 2008, 26:626-632.
97. Krause D.S., Van Etten R.A. Tyrosine kinases as targets for cancer therapy. N Engl J Med 2005, 353:172-187.
98. Verweij J., Casali P.G., Zalcberg J., et al. Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. Lancet 2004, 364:1127-1134.
99. Johnson B.E., Fischer T., Fischer B., et al. Phase II study of imatinib in patients with small cell lung cancer. Clin Cancer Res 2003, 9:5880-5887.
100. Kindler T., Breitenbuecher F., Marx A., et al. Efficacy and safety of imatinib in adult patients with c-kit-positive acute myeloid leukemia. Blood 2004, 103:3644-3654.
101. Druker B.J., Tamura S., Buchdunger E., et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 1996, 2:561-566.
102. Escudier B., Eisen T., Stadler W.M., et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007, 356:125-134.
103. Kantarjian H., Giles F., Wunderle L., et al. Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N Engl J Med 2006, 354:2542-2551.
104. Kantarjian H., Shah N.P., Hochhaus A., et al. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2010, 362:2260-2270.
105. Llovet J.M., Ricci S., Mazzaferro V., et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008, 359:378-390.
106. Talpaz M., Shah N.P., Kantarjian H., et al. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med 2006, 354:2531-2541.
107. Saglio G., Kim D.W., Issaragrisil S., et al. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med 2010, 362:2251-2259.
108. Kris M.G., Natale R.B., Herbst R.S., et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA 2003, 290:2149-2158.
109. Mok T.S., Wu Y.L., Thongprasert S., et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009, 361:947-957.
110. Shepherd F.A., Rodrigues Pereira J., Ciuleanu T., et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005, 353:123-132.
111. Chapman P.B., Hauschild A., Robert C., et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011, 364:2507-2516.
112. Kwak E.L., Bang Y.J., Camidge D.R., et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 2010, 363:1693-1703.
113. Bracarda S., Ruggeri E.M., Monti M., et al. Early detection, prevention and management of cutaneous adverse events due to sorafenib: Recommendations from the Sorafenib Working Group. Crit Rev Oncol Hematol 2011.
114. Fojo T. Commentary: novel therapies for cancer: why dirty might be better. Oncologist 2008, 13:277-283.
115. Cline M.J. Cancer chemotherapy. Major series in internal medicine 1971, 1-11. WB Saunders Co, Philadelphia, London, Toronto. L.L.H. Smith (Ed.).
116. Bonadonna G. Principi di chemioterapia antitumorale. Manuale di Oncología Medica 1983, 201-210. Masson Italia Editori, Milano. 2nd ed. G. Bonadonna (Ed.).
117. Hait W.N., Holland J.F., Frei E., Kufe D.W., Bast R.C., Hong W.K. Principles of medical oncology. Cancer medicine 2010, People's Medical Publishing House, Shelton, Connecticut. 8th ed. W.K. Hong, R.C. Bast, W.N. Hait, D.W. Kufe, R.E. Pollock, R.R. Weichselbaum, J.F. Holland, E. Frei (Eds.).
118. Galmarini C.M., Mackey J.R., Dumontet C. Nucleoside analogues: mechanisms of drug resistance and reversal strategies. Leukemia 2001, 15:875-890.
119. Goldie J.H., Coldman A.J. Genetic instability in the development of drug resistance. Semin Oncol 1985, 12:222-230.
120. Leonard G.D., Fojo T., Bates S.E. The role of ABC transporters in clinical practice. Oncologist 2003, 8:411-424.
121. Lowe S.W., Bodis S., McClatchey A., et al. p53 status and the efficacy of cancer therapy in vivo. Science 1994, 266:807-810.
122. Jain R.K. The next frontier of molecular medicine: delivery of therapeutics. Nat Med 1998, 4:655-657.
123. Galmarini C.M., Galmarini F.C. Multidrug resistance in cancer therapy: role of the microenvironment. Curr Opin Investig Drugs 2003, 4:1416-1421.
124. Tredan O., Galmarini C.M., Patel K., Tannock I.F. Drug resistance and the solid tumor microenvironment. J Natl Cancer Inst 2007, 99:1441-1454.
125. Galmarini F.C., Galmarini C.M., Sarchi M.I., Abulafia J., Galmarini D. Heterogeneous distribution of tumor blood supply affects the response to chemotherapy in patients with head and neck cancer. Microcirculation 2000, 7:405-410.
126. Jain R.K. Determinants of tumor blood flow: a review. Cancer Res 1988, 48:2641-2658.
127. Jain R.K. Barriers to drug delivery in solid tumors. Sci Am 1994, 271:58-65.
128. Brown J.M., Giaccia A.J. The unique physiology of solid tumors: opportunities (and problems) for cancer therapy. Cancer Res 1998, 58:1408-1416.
129. Less J.R., Posner M.C., Skalak T.C., Wolmark N., Jain R.K. Geometric resistance and microvascular network architecture of human colorectal carcinoma. Microcirculation 1997, 4:25-33.
130. Sevick E.M., Jain R.K. Viscous resistance to blood flow in solid tumors: effect of hematocrit on intratumor blood viscosity. Cancer Res 1989, 49:3513-3519.
131. Sevick E.M., Jain R.K. Effect of red blood cell rigidity on tumor blood flow: increase in viscous resistance during hyperglycemia. Cancer Res 1991, 51:2727-2730.
132. Eskey C.J., Koretsky A.P., Domach M.M., Jain R.K. 2H-nuclear magnetic resonance imaging of tumor blood flow: spatial and temporal heterogeneity in a tissue-isolated mammary adenocarcinoma. Cancer Res 1992, 52:6010-6019.
133. Hamberg L.M., Kristjansen P.E., Hunter G.J., Wolf G.L., Jain R.K. Spatial heterogeneity in tumor perfusion measured with functional computed tomography at 0.05 microliter resolution. Cancer Res 1994, 54:6032-6036.
134. Baxter L.T., Jain R.K. Transport of fluid and macromolecules in tumors. I. Role of interstitial pressure and convection. Microvasc Res 1989, 37:77-104.
135. Jain R.K. Transport of molecules across tumor vasculature. Cancer Metastasis Rev 1987, 6:559-593.
136. Boucher Y., Baxter L.T., Jain R.K. Interstitial pressure gradients in tissue-isolated and subcutaneous tumors: implications for therapy. Cancer Res 1990, 50:4478-4484.
137. Jain R.K. Transport of molecules in the tumor interstitium: a review. Cancer Res 1987, 47:3039-3051.
138. Tannock I.F., Lee C.M., Tunggal J.K., Cowan D.S., Egorin M.J. Limited penetration of anticancer drugs through tumor tissue: a potential cause of resistance of solid tumors to chemotherapy. Clin Cancer Res 2002, 8:878-884.
139. Vaupel P., Kallinowski F., Okunieff P. Blood flow, oxygen and nutrient supply, and metabolic microenvironment of human tumors: a review. Cancer Res 1989, 49:6449-6465.
140. Kim J.J., Tannock I.F. Repopulation of cancer cells during therapy: an important cause of treatment failure. Nat Rev Cancer 2005, 5:516-525.
141. Zhang L.Z., Zhang C.Q., Yan Z.Y., Yang Q.C., Jiang Y., Zeng B.F. Tumor-initiating cells and tumor vascularization. Pediatr Blood Cancer 2011, 56:335-340.
142. Demicheli R., Retsky M.W., Swartzendruber D.E., Bonadonna G. Proposal for a new model of breast cancer metastatic development. Ann Oncol 1997, 8:1075-1080.
143. Demicheli R., Terenziani M., Valagussa P., Moliterni A., Zambetti M., Bonadonna G. Local recurrences following mastectomy: support for the concept of tumor dormancy. J Natl Cancer Inst 1994, 86:45-48.
144. Folkman J. What is the evidence that tumors are angiogenesis dependent?. J Natl Cancer Inst 1990, 82:4-6.
145. O'Reilly M.S., Holmgren L., Chen C., Folkman J. Angiostatin induces and sustains dormancy of human primary tumors in mice. Nat Med 1996, 2:689-692.
146. O'Reilly M.S., Holmgren L., Shing Y., et al. Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 1994, 79:315-328.
147. Baum M., Demicheli R., Hrushesky W., Retsky M. Does surgery unfavourably perturb the "natural history" of early breast cancer by accelerating the appearance of distant metastases?. Eur J Cancer 2005, 41:508-515.
148. Demicheli R., Miceli R., Moliterni A., et al. Breast cancer recurrence dynamics following adjuvant CMF is consistent with tumor dormancy and mastectomy-driven acceleration of the metastatic process. Ann Oncol 2005, 16:1449-1457.
149. Duration and reintroduction of adjuvant chemotherapy for node-positive premenopausal breast cancer patients. J Clin Oncol 1996, 14:1885-1894. International Breast Cancer Study Group.
150. Castiglione-Gertsch M., Tattersall M., Hacking A., et al. Retreating recurrent breast cancer with the same CMF-containing regimen used as adjuvant therapy. The International Breast Cancer Study Group. Eur J Cancer 1997, 33:2321-2325.
151. Valagussa P., Brambilla C., Zambetti M., Bonadonna G. Salvage treatments in relapsing resectable breast cancer. Recent Results Cancer Res 1989, 115:69-76.
152. Bardwell A.J., Bardwell L., Wang Z., et al. Recent insights on DNA repair. The mechanism of damaged nucleotide excision in eukaryotes and its relationship to other cellular processes. Ann N Y Acad Sci 1994, 726:281-291.
153. Cornwell M.M., Tsuruo T., Gottesman M.M., Pastan I. ATP-binding properties of P glycoprotein from multidrug-resistant KB cells. FASEB J 1987, 1:51-54.
154. Scheffer G.L., Wijngaard P.L., Flens M.J., et al. The drug resistance-related protein LRP is the human major vault protein. Nat Med 1995, 1:578-582.
155. Komlodi-Pasztor E., Sackett D., Wilkerson J., Fojo T. Mitosis is not a key target of microtubule agents in patient tumors. Nat Rev Clin Oncol 2011.
156. Gleeson M.P., Hersey A., Montanari D., Overington J. Probing the links between in vitro potency, ADMET and physicochemical parameters. Nat Rev Drug Discov 2011, 10:197-208.
157. Shoemaker R.H. The NCI60 human tumour cell line anticancer drug screen. Nat Rev Cancer 2006, 6:813-823.
158. De Graaf T.W., Slot S.S., Peters G.J., Van Dijk W. Changes in glycosylation of L1210 cells after exposure to various antimetabolites. Eur J Cancer 1993, 29A:1760-1765.
159. Pels Rijcken W.R., Telleman F., Peters G.J., Ferwerda W. Incorporation of 5-fluorouracil into nucleotide sugars and the effect on glycoconjugates in rat hepatoma cells and hepatocytes. Adv Exp Med Biol 1989, 253B:313-320.
160. Lowe J.A., Jones P., Wilson D.M. Network biology as a new approach to drug discovery. Curr Opin Drug Discov Devel 2010, 13:524-526.
161. Borg C., Terme M., Taieb J., et al. Novel mode of action of c-kit tyrosine kinase inhibitors leading to NK cell-dependent antitumor effects. J Clin Invest 2004, 114:379-388.
162. Menard C., Blay J.Y., Borg C., et al. Natural killer cell IFN-gamma levels predict long-term survival with imatinib mesylate therapy in gastrointestinal stromal tumor-bearing patients. Cancer Res 2009, 69:3563-3569.
163. Lee S.J., Wang J.Y. Exploiting the promiscuity of imatinib. J Biol 2009, 8:30.
164. Jimeno A., Hidalgo M. Multitargeted therapy: can promiscuity be praised in an era of political correctness?. Crit Rev Oncol Hematol 2006, 59:150-158.
165. Larkin J.M., Eisen T. Kinase inhibitors in the treatment of renal cell carcinoma. Crit Rev Oncol Hematol 2006, 60:216-226.
166. Diasio R.B., Beavers T.L., Carpenter J.T. Familial deficiency of dihydropyrimidine dehydrogenase. Biochemical basis for familial pyrimidinemia and severe 5-fluorouracil-induced toxicity. J Clin Invest 1988, 81:47-51.
167. Egorin M.J., Van Echo D.A., Tipping S.J., et al. Pharmacokinetics and dosage reduction of cis-diammine(1,1-cyclobutanedicarboxylato)platinum in patients with impaired renal function. Cancer Res 1984, 44:5432-5438.
168. Mathijssen R.H., van Alphen R.J., Verweij J., et al. Clinical pharmacokinetics and metabolism of irinotecan (CPT-11). Clin Cancer Res 2001, 7:2182-2194.
169. Zhou S. Clinical pharmacogenomics of thiopurine S-methyltransferase. Curr Clin Pharmacol 2006, 1:119-128.
170. Ng T., Chan A. Dosing modifications of targeted cancer therapies in patients with special needs: evidence and controversies. Crit Rev Oncol Hematol 2012, 81:58-74.
171. Delbaldo C., Chatelut E., Re M., et al. Pharmacokinetic-pharmacodynamic relationships of imatinib and its main metabolite in patients with advanced gastrointestinal stromal tumors. Clin Cancer Res 2006, 12:6073-6078.
172. Gambacorti-Passerini C., Zucchetti M., Russo D., et al. Alpha1 acid glycoprotein binds to imatinib (STI571) and substantially alters its pharmacokinetics in chronic myeloid leukemia patients. Clin Cancer Res 2003, 9:625-632.
173. Widmer N., Decosterd L.A., Csajka C., et al. Population pharmacokinetics of imatinib and the role of alpha-acid glycoprotein. Br J Clin Pharmacol 2006, 62:97-112.
174. Lynch T.J., Bell D.W., Sordella R., et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004, 350:2129-2139.
175. Fukuoka M., Yano S., Giaccone G., et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected]. J Clin Oncol 2003, 21:2237-2246.
176. Giaccone G., Herbst R.S., Manegold C., et al. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial-INTACT 1. J Clin Oncol 2004, 22:777-784.
177. Herbst R.S., Giaccone G., Schiller J.H., et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial-INTACT 2. J Clin Oncol 2004, 22:785-794.
178. Albanell J., Rojo F., Averbuch S., et al. Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: histopathologic and molecular consequences of receptor inhibition. J Clin Oncol 2002, 20:110-124.
179. Kimmelman J., London A.J. Predicting harms and benefits in translational trials: ethics, evidence, and uncertainty. PLoS Med 2011, 8:e1001010.
180. Muggia F.M., Peters G.J., Landolph J.R. XIII International Charles Heidelberger Symposium and 50 years of fluoropyrimidines in cancer therapy held on September 6 to 8, 2007 at New York University Cancer Institute, Smilow Conference Center. Mol Cancer Ther 2009, 8:992-999.
181. Field J.B. 5-Fluorouracil (Nsc-19893) treatment of advanced cancer in ambulatory patients. Cancer Chemother Rep 1963, 33:45-49.
182. Sharp G.S., Benefiel W.W. 5-Fluorouracil in the treatment of inoperable carcinoma of the colon and rectum. Cancer Chemother Rep 1962, 20:97-101.
183. Diasio R.B., Harris B.E. Clinical pharmacology of 5-fluorouracil. Clin Pharmacokinet 1989, 16:215-237.
184. Chirstophidis N., Vajda F.J., Lucas I., Drummer O., Moon W.J., Louis W.J. Fluorouracil therapy in patients with carcinoma of the large bowel: a pharmacokinetic comparison of various rates and routes of administration. Clin Pharmacokinet 1978, 3:330-336.
185. Ramirez G., Korbitz B.C., Davis H.L., Ansfield F.J. Comparative study of monthly courses versus weekly doses of 5-fluorouracil (NSC-19893). Cancer Chemother Rep 1969, 53:243-247.
186. Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. J Clin Oncol 1998, 16:301-308. Meta-analysis Group In Cancer.
187. Harris B.E., Song R., Soong S.J., Diasio R.B. Relationship between dihydropyrimidine dehydrogenase activity and plasma 5-fluorouracil levels with evidence for circadian variation of enzyme activity and plasma drug levels in cancer patients receiving 5-fluorouracil by protracted continuous infusion. Cancer Res 1990, 50:197-201.
188. Seifert P., Baker L.H., Reed M.L., Vaitkevicius V.K. Comparison of continuously infused 5-fluorouracil with bolus injection in treatment of patients with colorectal adenocarcinoma. Cancer 1975, 36:123-128.
189. Shah A., MacDonald W., Goldie J., Gudauskas G., Brisebois B. 5-FU infusion in advanced colorectal cancer: a comparison of three dose schedules. Cancer Treat Rep 1985, 69:739-742.
190. Park J.G., Collins J.M., Gazdar A.F., et al. Enhancement of fluorinated pyrimidine-induced cytotoxicity by leucovorin in human colorectal carcinoma cell lines. J Natl Cancer Inst 1988, 80:1560-1564.
191. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate. J Clin Oncol 1992, 10:896-903. Advanced Colorectal Cancer Meta-Analysis Project.
192. Andre T., Boni C., Mounedji-Boudiaf L., et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 2004, 350:2343-2351.
193. Douillard J.Y., Cunningham D., Roth A.D., et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 2000, 355:1041-1047.
194. Kohne C.H., van Cutsem E., Wils J., et al. Phase III study of weekly high-dose infusional fluorouracil plus folinic acid with or without irinotecan in patients with metastatic colorectal cancer: European Organisation for Research and Treatment of Cancer Gastrointestinal Group Study 40986. J Clin Oncol 2005, 23:4856-4865.
195. Kuebler J.P., Wieand H.S., O'Connell M.J., et al. Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07. J Clin Oncol 2007, 25:2198-2204.
196. Demicheli R., Biganzoli E., Ardoino I., et al. Recurrence and mortality dynamics for breast cancer patients undergoing mastectomy according to estrogen receptor status: different mortality but similar recurrence. Cancer Sci 2010, 101:826-830.
197. Demicheli R., Retsky M.W., Hrushesky W.J., Baum M. Tumor dormancy and surgery-driven interruption of dormancy in breast cancer: learning from failures. Nat Clin Pract Oncol 2007, 4:699-710.
198. Stein W.D., Figg W.D., Dahut W., et al. Tumor growth rates derived from data for patients in a clinical trial correlate strongly with patient survival: a novel strategy for evaluation of clinical trial data. Oncologist 2008, 13:1046-1054.
199. Stein W.D., Gulley J.L., Schlom J., et al. Tumor regression and growth rates determined in five intramural NCI prostate cancer trials: the growth rate constant as an indicator of therapeutic efficacy. Clin Cancer Res 2011, 17:907-917.
200. Stein W.D., Yang J., Bates S.E., Fojo T. Bevacizumab reduces the growth rate constants of renal carcinomas: a novel algorithm suggests early discontinuation of bevacizumab resulted in a lack of survival advantage. Oncologist 2008, 13:1055-1062.
201. Frei E., Canellos G.P. Dose: a critical factor in cancer chemotherapy. Am J Med 1980, 69:585-594.
202. Hryniuk W.M. More is better. J Clin Oncol 1988, 6:1365-1367.
203. Pasquier E., Kavallaris M., Andre N. Metronomic chemotherapy: new rationale for new directions. Nat Rev Clin Oncol 2010, 7:455-465.
204. Gatenby R.A., Silva A.S., Gillies R.J., Frieden B.R. Adaptive therapy. Cancer Res 2009, 69:4894-4903.
205. Penel N., Adenis A., Bocci G. Cyclophosphamide-based metronomic chemotherapy: after 10 years of experience, where do we stand and where are we going?. Crit Rev Oncol Hematol 2011.
206. Ocana A., Tannock I.F. When are "positive" clinical trials in oncology truly positive?. J Natl Cancer Inst 2011, 103:16-20.
207. Feinstein A.R. Meta-analysis: statistical alchemy for the 21st century. J Clin Epidemiol 1995, 48:71-79.
208. Fojo T., Parkinson D.R. Biologically targeted cancer therapy and marginal benefits: are we making too much of too little or are we achieving too little by giving too much?. Clin Cancer Res 2010, 16:5972-5980.
209. Booth C.M. Evaluating patient-centered outcomes in the randomized controlled trial and beyond: informing the future with lessons from the past. Clin Cancer Res 2010, 16:5963-5971.
210. Seruga B., Hertz P.C., Wang L., et al. Absolute benefits of medical therapies in phase III clinical trials for breast and colorectal cancer. Ann Oncol 2010, 21:1411-1418.
211. Demicheli R., Coradini D. Gene regulatory networks: a new conceptual framework to analyse breast cancer behaviour. Ann Oncol 2010.
212. Goss P.E., Chambers A.F. Does tumour dormancy offer a therapeutic target?. Nat Rev Cancer 2010, 10:871-877.
213. Schipper H., Goh C.R., Wang T.L. Shifting the cancer paradigm: must we kill to cure?. J Clin Oncol 1995, 13:801-807.
214. Ruggiero R.A., Bustuoabad O.D. The biological sense of cancer: a hypothesis. Theor Biol Med Model 2006, 3:43.
215. Diop-Frimpong B., Chauhan V.P., Krane S., Boucher Y., Jain R.K. Losartan inhibits collagen I synthesis and improves the distribution and efficacy of nanotherapeutics in tumors. Proc Natl Acad Sci U S A 2011, 108:2909-2914.
216. Jain R.K., Stylianopoulos T. Delivering nanomedicine to solid tumors. Nat Rev Clin Oncol 2010, 7:653-664.